DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 6,123,943 Baba Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 6,123,943 Baba Et Al USOO61239.43A United States Patent (19) 11 Patent Number: 6,123,943 Baba et al. (45) Date of Patent: Sep. 26, 2000 54 NF-KBACTIVITY INHIBITOR 8-301761 11/1996 Japan ............................. A61K 31/47 75 Inventors: Masanori Baba, Kagoshima; Minoru OTHER PUBLICATIONS Ono, Tokyo, both of Japan Sato et al. Eur. J. Pharmacol. (1982) 83: 91-95. 73 Assignee: Kaken Shoyaku Co., Ltd., Tokyo, Japan Primary Examiner Jean C. Witz Attorney, Agent, or Firm Sughrue, Mion, Zinn, Macpeak 21 Appl. No.: 09/037,712 & Seas, PLLC 22 Filed: Mar 10, 1998 57 ABSTRACT 30 Foreign Application Priority Data This invention relates to an NF-kB activity inhibitor which contains alkaloids originated from a plant belonging to the Dec. 22, 1997 JP Japan .................................... 9-353879 genus Stephania of the family Menspermaceae, derivatives thereof and Salts thereof, as the active components, to an (51) Int. Cl." ..................................................... A61K 35/78 agent for use in the treatment and prevention of diseases 52 U.S. Cl. ....................... 424/195.1; 514/308; 514/387; upon which the NF-kB activity inhibiting action is effective 514/415 and to an inhibitor of the expression of related genes. Since 58 Field of Search ......................... 424/195.1; 514/387, Said active components exert an action to inhibit transcrip 514/308, 415; 546/140,139; 534/790 tion of DNA having an NF-kB recognition sequence by inhibiting the activity of NF-kB, the drug of the present 56) References Cited invention can inhibit expression of genes of certain Sub U.S. PATENT DOCUMENTS stances Such as cytokines, inflammatory cytokine receptor antagonists, MHC class I, MHC class II, B2 microglobulin, 5,025,020 6/1991 Van Dyke ............................... 514/280 5,534,523 7/1996 Ono et al. ............................... 514/308 immunoglobulin light chain, Serum amyloid A, 5,627,195 5/1997 Hu ................ ... 514/321 angiotensinogen, complement B, complement C4, C-myc 5,641,773 6/1997 Pardee et al. ........................... 514/221 gene, HIV, SV40, CMV, adenovirus and the like, so that the inventive drug is useful in treating and/or preventing various FOREIGN PATENT DOCUMENTS diseases in which these Substances are taking roles. 0 476 391 A2 3/1992 European Pat. Off. ... A61K 31f47 1-233220 9/1989 Japan. 6 Claims, No Drawings 6,123,943 1 2 NF-KBACTIVITY INHIBITOR genus Stephania of the family Menspermaceae, as its active ingredient, inhibits production of TNFC, interleukin-6 (to be FIELD OF THE INVENTION referred to as IL-6 hereinafter in Some cases) and This invention relates to an NF-kB activity inhibitor, to interleukin-8 (to be referred to as IL-8 hereinafter in some agents for use in the treatment and prevention of diseases cases) (JP-A-8-301761, the term “JP-A” as used herein upon which NF-kB activity inhibiting action is effective, means an “unexamined published Japanese patent particularly an agent for the treatment and prevention of application'). inflammatory diseases, an agent for the treatment and pre Phospholipid which constitutes the biological membrane vention of autoimmune diseases and an agent for the treat releases arachidonic acid by the action of phospholipase A. ment and prevention of Viral diseases, and to a gene expres Leukotriene, thromboxane, prostaglandine and the like are Sion inhibitor. produced from the arachidonic acid by the action of 5-lipoxygenase or cyclooxygenase. These Substances exert BACKGROUND OF THE INVENTION complex physiological activities and take important roles in DNA as the Substance of genes is regulated by various the maintenance and regulation of the living body. In the factors, and expression of its genetic information is con 15 living body, various cytokines are released by receiving trolled thereby. For example, transcription of genetic infor various types of Stimulation and cause inflammatory reac mation from DNA to RNA is controlled by a plurality of tions. The prior art drugs inhibit expression of histamine and DNA binding proteins which recognizes Several to Scores of leukotriene B4 or prostaglandine E2 or the like inflamma nucleotide Sequences on the gene and bind thereto. NF-KB tory protein by the antagonism on mediator receptors of (nuclear factor-KB) known as one of such DNA binding histamine and the like or by the inhibition of lipoxygenase, proteins is present in the nuclear extract of B cells which are cyclooxygenase and the like metabolic enzymes in the antibody-producing cells and has been identified as a factor arachidonic acid cascade. However, effects of non-Steroidal that binds to the enhancer of immunoglobulin K chain (Igk) drugs are expected for only Symptomatic therapy and not gene. With the progreSS of Studies on this factor, it has been Sufficient as radical therapy, while Steroid drugs are effective revealed that this is a transcription factor which takes part in 25 but have a problem in that they cannot be administered for the expression induction of a large number of genes that are a prolonged period of time due to their Strong Side effects. induced by Stimulation and is broadly concerned in the Particularly, autoimmune disease and the like inflammatory regulation of Vital phenomenon. diseases become chronic in many cases and therefore require This NF-kB is generally present in the cytoplasm in the prolonged medical treatments, So that drugs having Side form of a complex in which its homodimer of proteins effects are not applicable to Such diseases. In addition, having a molecular weight of 50 kD or its heterodimer of a NF-kB takes an important role in the replication of HIV-1, protein of 50 kD in molecular weight and a protein of 65 kD so that search for a substance capable of inhibiting NF-KB in molecular weight is bonded to a protein called I-KB which activity is expected for not only its anti-inflammatory effects inhibits activity of the dimer. When a certain stimulation is but also inhibition of acquired immunodeficiency Syndrome given to the cells, I-KB is modified and released from the 35 (AIDS and the like) by its effect to inhibit transcription of complex to cause activation of NF-kB, so that the dimer is long terminal repeat (LTR) of HIV-1, namely replication of transferred into the nucleus and its DNA binding activity the virus. becomes detectable. It is known that this activity is gener SUMMARY OF THE INVENTION ated as a result of direct activation, not mediated by the 40 expression of other genes Such as Second messengers and the In view of the above, it therefore becomes an object of the like. present invention to provide an NF-kB activity inhibitor. In addition, the NF-kB binding sequence on DNA has Another object of the present invention is to provide an been found in various genes and it has been shown that it is agent for the treatment and prevention of diseases upon actually important for the expression of the function of 45 which NF-kB activity inhibiting action is effective. Sill genes. The binding sequence of NF-kB (KB motif) is com another object of the present invention is to provide an posed of about 10 bases having a common Sequence which inhibitor of the expression of genes based on the NF-KB Starts with a cluster of G (guanine) and ends with a cluster activity inhibiting action. of C (cytosine) (consensus sequence 5'-GGGRNNYCCC The inventors of the present invention have conducted 3')(SEQ ID NO:1. However, a number of sequences to 50 intensive Studies on the methods and Substances which can which DNA binding proteins can be bonded are present on radically inhibit various inflammatory cytokines and found the genes of interleukin-1 (to be referred to as IL-1 herein as the results that alkaloids originated from a plant belong after in Some cases) and tumor necrosis factor (to be referred ing to the genus Stephania of the family Menspermaceae, to as TNF hereinafter in some cases) which are known as derivatives thereof and salts thereof can inhibit various inflammatory proteins, and it is known that the NF-KB 55 cytokines and the like at the gene level based on their binding sequence is also present therein (Clark, B. D. et al., transcription factor NF-kB activity inhibiting action and Nucl. Acids Res., 14, 7898, 1984; Nedospasov, S. A. et al., have an activity to inhibit transcription of HIV-1 LTR. The Cold Spring Harb. Symp. Quant. Biol., 51, 611, 1986). present invention has been accomplished on the basis of Actually, it has been reported that the binding of NF-KB these findings. inhibits transcription to mRNA (Hiscott, J. et al., Mol. Cell. 60 Accordingly, the present invention relates to an NF-KB Biol., 13, 6231, 1993; Collart, M. A. et al., Mol. Cell. Biol., activity inhibitor which comprises, as its active ingredient, at 10, 1498, 1990). least one compound Selected from the group consisting of AS a Substance which inhibits the transcription factor of alkaloids originated from a plant belonging to the genus NF-kB, an NF-kB binding protein has been disclosed in Stephania of the family Menspermaceae, derivatives thereof European Patent 584238. 65 and Salts thereof; to an agent for the treatment and preven In addition, it has been reported that a composition which tion of diseases upon which NF-kB activity inhibiting action contains an alkaloid originated from a plant belonging to the is effective (particularly an agent for the treatment and 6,123,943 3 4 prevention of inflammatory diseases, an agent for the treat isoquinoline alkaloids, FK-3000, Sinomenine, cephamonine, ment and prevention of autoimmune diseases and an agent tannagine, cephamuline and the like morphinan alkaloids, for the treatment and prevention of viral diseases); and to an lastourVilline, isocorydine, corydine and the like aporphine gene expression inhibitor.
Load more

Recommended publications
  • United States Patent [191 [11] Patent Number: 4,758,639 Koyanagi Et Al
    United States Patent [191 [11] Patent Number: 4,758,639 Koyanagi et al. [45] Date of Patent: Jul. 19, 1988 [54] PROCESS FOR PRODUCTION OF VINYL [56] References Cited POLYMER . U.S. PATENT DOCUMENTS [75] Inventors: Shunichi Koyanagi, Yokohama; 3,923,765 12/1975 Goetze et al. ....................... .. 526/62 Hajime Kutamura, Ichihara; 4,049,895 9/1977 McOnie et al. ..... .. 526/62 Toshihide Shimizu; Ichiro Kaneko, 4,539,230 9/ 1985 Shimizu et al. ................. .. 526/62 X both of Ibaraki, all of Japan Primary Examiner-Joseph L. Schofer Assistant Examiner-F. M. Teskin [73] Assignee: Shin-Etsu Chemical Co., Ltd., Tokyo, Attorney, Agent, or Firm—0blon, Fisher, Spivak, Japan McClelland & Maier [21] Appl. No.: 94,020 [57] ABSTRACT [22] Filed: Sep. 3, 1987 A process for production of a vinyl polymer by suspen sion polymerization or emulsion polymerization of at Related US. Application Data least one kind of vinyl monomer in an aqueous medium is disclosed. [63] Continuation of Ser. No. 765,803, Aug. 15, 1985, aban In this process, the polymerization is carried out in a cloned. polymerizer, the inner wall surface and portions of the [30] Foreign Application Priority Data auxiliary equipment thereof which may come into contact with the monomer during polymerization hav Aug. 17, 1984 [JP] Japan ........ .. .. 59471045 ing a surface roughness of not greater than 5 pm and Aug. 17, 1984 [JP] Japan .............................. .. 59-171046 being previously coated with a scaling preventive com [51] Int. Cl.‘ ......................... .. C08F 2/18; C08F 2/22; prising at least one selected from dyes, pigments and CO8F 2/44 aromatic or heterocyclic compounds having at least 5 [52] US.
    [Show full text]
  • Natural Products As Chemopreventive Agents by Potential Inhibition of the Kinase Domain in Erbb Receptors
    Supplementary Materials: Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErBb Receptors Maria Olivero-Acosta, Wilson Maldonado-Rojas and Jesus Olivero-Verbel Table S1. Protein characterization of human HER Receptor structures downloaded from PDB database. Recept PDB resid Resolut Name Chain Ligand Method or Type Code ues ion Epidermal 1,2,3,4-tetrahydrogen X-ray HER 1 2ITW growth factor A 327 2.88 staurosporine diffraction receptor 2-{2-[4-({5-chloro-6-[3-(trifl Receptor uoromethyl)phenoxy]pyri tyrosine-prot X-ray HER 2 3PP0 A, B 338 din-3-yl}amino)-5h-pyrrolo 2.25 ein kinase diffraction [3,2-d]pyrimidin-5-yl]etho erbb-2 xy}ethanol Receptor tyrosine-prot Phosphoaminophosphonic X-ray HER 3 3LMG A, B 344 2.8 ein kinase acid-adenylate ester diffraction erbb-3 Receptor N-{3-chloro-4-[(3-fluoroben tyrosine-prot zyl)oxy]phenyl}-6-ethylthi X-ray HER 4 2R4B A, B 321 2.4 ein kinase eno[3,2-d]pyrimidin-4-ami diffraction erbb-4 ne Table S2. Results of Multiple Alignment of Sequence Identity (%ID) Performed by SYBYL X-2.0 for Four HER Receptors. Human Her PDB CODE 2ITW 2R4B 3LMG 3PP0 2ITW (HER1) 100.0 80.3 65.9 82.7 2R4B (HER4) 80.3 100 71.7 80.9 3LMG (HER3) 65.9 71.7 100 67.4 3PP0 (HER2) 82.7 80.9 67.4 100 Table S3. Multiple alignment of spatial coordinates for HER receptor pairs (by RMSD) using SYBYL X-2.0. Human Her PDB CODE 2ITW 2R4B 3LMG 3PP0 2ITW (HER1) 0 4.378 4.162 5.682 2R4B (HER4) 4.378 0 2.958 3.31 3LMG (HER3) 4.162 2.958 0 3.656 3PP0 (HER2) 5.682 3.31 3.656 0 Figure S1.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-AROMOLINE 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 4 (+)-CEPHARANTHINE 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 2 (+)-ISOLARICIRESINOL 1 (+)-NORTRACHELOGENIN 1 (+)-PRAERUPTORUM-A 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (+)-TENUIPINE 1 (+)-TETRANDRINE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 1 (-)-APOGLAZIOVINE 2 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANADINE 1 (-)-CURINE 1 Chemical Activity Count (-)-DAURISOLINE 1 (-)-DICENTRINE 1 (-)-EMETINE 1 (-)-EPICATECHIN 3 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 2 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 2 (-)-EUDESMIN 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-IBOGAMINE 1 (-)-STEPHOLIDINE 1 (-)-TENUIPINE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 2 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 1-ETHYL-BETA-CARBOLINE 2 1-HYDROXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-METHOXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10,6-HONOKIOL 1
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano Et Al
    US 20090269772A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano et al. (43) Pub. Date: Oct. 29, 2009 (54) SYSTEMS AND METHODS FOR Publication Classification IDENTIFYING COMBINATIONS OF (51) Int. Cl. COMPOUNDS OF THERAPEUTIC INTEREST CI2O I/68 (2006.01) CI2O 1/02 (2006.01) (76) Inventors: Andrea Califano, New York, NY G06N 5/02 (2006.01) (US); Riccardo Dalla-Favera, New (52) U.S. Cl. ........... 435/6: 435/29: 706/54; 707/E17.014 York, NY (US); Owen A. (57) ABSTRACT O'Connor, New York, NY (US) Systems, methods, and apparatus for searching for a combi nation of compounds of therapeutic interest are provided. Correspondence Address: Cell-based assays are performed, each cell-based assay JONES DAY exposing a different sample of cells to a different compound 222 EAST 41ST ST in a plurality of compounds. From the cell-based assays, a NEW YORK, NY 10017 (US) Subset of the tested compounds is selected. For each respec tive compound in the Subset, a molecular abundance profile from cells exposed to the respective compound is measured. (21) Appl. No.: 12/432,579 Targets of transcription factors and post-translational modu lators of transcription factor activity are inferred from the (22) Filed: Apr. 29, 2009 molecular abundance profile data using information theoretic measures. This data is used to construct an interaction net Related U.S. Application Data work. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the (60) Provisional application No. 61/048.875, filed on Apr.
    [Show full text]
  • Botulinum Toxin
    Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").
    [Show full text]
  • Novel Chemical Tools for the Modulation of Two Pore Channel 2
    Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig‐Maximilians‐Universität München NOVEL CHEMICAL TOOLS FOR THE MODULATION OF TWO PORE CHANNEL 2 Susanne Daniela Gerndt aus Schweinfurt 2020 Erklärung Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von Herrn Prof. Franz Bracher betreut. Eidesstattliche Versicherung Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. München, den 29.06.2020 ____________________________ Susanne Daniela Gerndt Dissertation eingereicht am: 01.07.2020 1. Gutachter: Prof. Dr. Franz Bracher 2. Gutachter: Prof. Dr. Dr. Christian Grimm Mündliche Prüfung am 27.07.2020 Danksagung An dieser Stelle möchte ich mich ganz herzlich bei allen bedanken, die diese Arbeit durch viele große und kleine Beiträge erst ermöglicht haben: Allen voran Herrn Prof. Dr. Franz Bracher für dieses interessante und abwechslungsreiche Thema und seine stets großzügige Unterstützung und Förderung während der vergangenen Jahre. Ebenso bedanken möchte ich mich bei den Mitgliedern der Prüfungskommission, vor allem bei Prof. Dr. Dr. Christian Grimm, nicht nur für die freundliche Übernahme des Koreferats, sondern auch für die Möglichkeit mich in ein mir fachfremdes Thema einzuarbeiten und viel Neues zu lernen. Weiter möchte ich auch meinen Kooperationspartnern danken, sei es in München Frau Prof. Dr. Angelika Vollmar, in Leipzig Prof. Dr. Michael Schaefer oder anderswo. Bei den Mitarbeitern der Analytikabteilung der Chemie und Pharmazie bedanke ich mich auch recht herzlich für die zahlreichen Messungen und die Hilfe bei analytischen Fragestellungen. Einen herzlichen Dank richte ich auch an die Arbeitsgruppen Biel, Grimm und Schaefer, die mich im Rahmen gemeinsamer Kooperationen freundlich aufgenommen und unterstützt haben.
    [Show full text]
  • Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs
    molecules Review Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs Sharna-kay Daley 1 and Geoffrey A. Cordell 1,2,* 1 Natural Products Inc., Evanston, IL 60202, USA; [email protected] 2 Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA * Correspondence: [email protected] Abstract: An overview is presented of the well-established role of alkaloids in drug discovery, the application of more sustainable chemicals, and biological approaches, and the implementation of information systems to address the current challenges faced in meeting global disease needs. The necessity for a new international paradigm for natural product discovery and development for the treatment of multidrug resistant organisms, and rare and neglected tropical diseases in the era of the Fourth Industrial Revolution and the Quintuple Helix is discussed. Keywords: alkaloids; drug discovery; fourth industrial revolution; quintuple helix; neglected tropical diseases; multidrug resistance; genomics; artificial intelligence 1. Introduction Citation: Daley, S.-k.; Cordell, G.A. 1.1. Alkaloids, Drug Discovery, and the Fourth Industrial Revolution Alkaloids in Contemporary Drug Alkaloids are a paradox and an enigma. Inexplicable, contradictory, mysterious, Discovery to Meet Global Disease and yet essential for all forms of life. There are the alkaloids we love as spices (capsaicin, Needs. Molecules 2021, 26, 3800. piperine, and the Murraya alkaloids), those we fear as toxins (batrachotoxin, strychnine, and https://doi.org/10.3390/ aconitine), those which affect perceptions in the brain (psilocin, N,N-dimethyltryptamine, molecules26133800 and ibogaine), and there is caffeine, the global stimulant of coffee, tea, maté, and guarana. There are those alkaloids which can relieve pain and, in another context, elicit pain and Academic Editors: Maria José enormous disruption in society (morphine and cocaine), and alkaloids whose diverse Umbelino Ferreira and Juan impacts can strain health care systems (nicotine).
    [Show full text]
  • A Yeast Platform for High-Level Synthesis of Tetrahydroisoquinoline Alkaloids
    ARTICLE https://doi.org/10.1038/s41467-020-17172-x OPEN A yeast platform for high-level synthesis of tetrahydroisoquinoline alkaloids Michael E. Pyne1,2, Kaspar Kevvai 1,2, Parbir S. Grewal 3, Lauren Narcross1,2, Brian Choi 3, ✉ Leanne Bourgeois1,2, John E. Dueber 4,5 & Vincent J. J. Martin 1,2 The tetrahydroisoquinoline (THIQ) moiety is a privileged substructure of many bioactive natural products and semi-synthetic analogs. Plants manufacture more than 3,000 THIQ 1234567890():,; alkaloids, including the opioids morphine and codeine. While microbial species have been engineered to synthesize a few compounds from the benzylisoquinoline alkaloid (BIA) family of THIQs, low product titers impede industrial viability and limit access to the full chemical space. Here we report a yeast THIQ platform by increasing production of the central BIA intermediate (S)-reticuline to 4.6 g L−1, a 57,000-fold improvement over our first-generation strain. We show that gains in BIA output coincide with the formation of several substituted THIQs derived from amino acid catabolism. We use these insights to repurpose the Ehrlich pathway and synthesize an array of THIQ structures. This work provides a blueprint for building diverse alkaloid scaffolds and enables the targeted overproduction of thousands of THIQ products, including natural and semi-synthetic opioids. 1 Department of Biology, Concordia University, Montréal, QC, Canada. 2 Centre for Applied Synthetic Biology, Concordia University, Montréal, QC, Canada. 3 Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, CA, USA. 4 Department of Bioengineering, University of California, Berkeley, Berkeley, CA, USA. 5 Biological Systems & Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
    [Show full text]
  • CP 7321.008, Dietary Supplements – Foreign and Domestic Inspections
    FOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM 7321.008 CHAPTER 21 – FOOD COMPOSITION, STANDARDS, LABELING, AND ECONOMICS SUBJECT: IMPLEMENTATION DIETARY SUPPLEMENTS – FOREIGN AND DOMESTIC DATE: INSPECTIONS, SAMPLING, AND IMPORTS 09/30/2020 DATA REPORTING PRODUCT CODES PRODUCT/ASSIGNMENT CODES (PAC) All Human Dietary REPORT PROGRAM ACTIVITIES UNDER THE Supplements FOLLOWING PAC CODES: Industry Code: 21008 all sample collection and analysis 54 21008F all full scope inspections of dietary supplement Subclass Code: manufacturers under 21 CFR part 111 B, C, and Y only 21008D all inspections of dietary supplement distribution USE APPROPRIATE facilities under 21 CFR part 111 PRODUCT CODES 21008L all limited focus inspections of dietary supplement manufacturers under 21 CFR part 111 21008W all inspections of dietary supplement warehouse facilities under 21 CFR part 111 21R829 all activities involving nutritional health fraud FIELD REPORTING REQUIREMENTS: The Office of Regulatory Affairs (ORA) field division completes the Establishment Inspection Report (EIR), including an inspection classification consistent with Field Management Directive (FMD) 86 and FDA policies including this compliance program, within ORA established timeframes. The ORA division files the inspection documents electronically no later than 30 working days from the close of the inspection using the appropriate module (eNSpect, or Compliance Management System (CMS)) accessible to both ORA and Center for Food Safety and Applied Nutrition (CFSAN). ORA
    [Show full text]
  • Natural Products in Chemical Biology Natural Products in Chemical Biology
    NATURAL PRODUCTS IN CHEMICAL BIOLOGY NATURAL PRODUCTS IN CHEMICAL BIOLOGY Edited by NATANYA CIVJAN A JOHN WILEY & SONS, INC., PUBLICATION Copyright © 2012 by John Wiley & Sons, Inc. All rights reserved Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com.Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate.
    [Show full text]
  • Cardiovascular Effects of Plant Secondary Metabolites Norarmepavine, Coclaurine and Norcoclaurine
    PHYTOTHERAPY RESEARCH, VOL. 12, 103-109 (1998) Cardiovascular Effects of Plant Secondary Metabolites Norarmepavine, Coclaurine and Norcoclaurine M.A. Morales,·· S.E. Bustamante,· G. Brito,· D. Paz2 and B. K. Cassels3 ¡Departamento de Farmacología, Facultad de Medicina, Universidad de Chile, Casilla 70 000, Santiago, Chile 2U.I.M. Farmacología de Productos Naturales, C.M.N. Siglo XXI, IMSS, México 3Departamento de Química, Facultad de Ciencias, Universidad de Chile, Santiago, Chile Tbe cardiovascular etTeets of (±)-norannepavine, a benzylisoquinoline alkaloid of natural origin, have been detennined on anaesthetized rats in vivo, on spontaneously beating atria and on aortic smooth muscle. In aorta, the etTeets of (±)-coclaurine and (±)-norcoclaurine, benzylisoquinolines with a related structure, were a1so compared. (±)-Norarmepavine (10 mg/kg i.v.) decreased the mean arterial pressure and heart rate by 45% and 21 %, respectively. (±).Norannepavine (10-5_10-3 M) showed a negative chronotropic etTect on rat-iso· lated atria, decreasing the spontaneous frequency by about 54%. Aortic rings contracted with KCI 70 mM were relaxed in a concentration-dependent manner by (±). norannepavine, (±)-coclaurine and (±)-norcoclaurine (10-6-10-3 M). The two earlier alkaloids exhibited an efficacy similar to verapamil, relaxing the aortic rings by 100%. (±)-Norcoclaurine exhibited a lower efficacy. These results point to the importance of methylation of these compounds. The rank order of potency was: (±)·verapamil > (±)-norarmepavine > (±)-norcoclaurine > (±)-coclaurine. The alkaloids shifted to the right the ealcium-dependent contraction eurves, denoting a calcium antagonist-like etTect; however, only a 10-fold increment of (±)-noreoclaurine concentration produced an equivalent etTect. Our results demonstrate the hypotensive and bradycardic properties of (±)-noranne• pavine.
    [Show full text]
  • Are Shown B Gene Numbera
    Tab le S1. A list of all the genes analyzed in the microarray analysis and whose signal ratios (-N/+N) are shown Gene numbera Gene producta Ratio (-N/+N)b CMG018C Nitrate transporter 7.64 ± 1.17 CMK117C Similar to Protein phosphatase 2C 6.41 ± 0.69 CMT527C Hypothetical protein 4.97 ± 0.49 CMT526C High affinity ammonium transporter 4.92 ± 1.59 CMS301C Hypothetical protein 4.51 ± 0.96 CME096C Similar to RNA binding protein HUA1 4.34 ± 0.44 CMN035C Hypothetical protein 4.21 ± 0.66 CMS095C Hypothetical protein 3.92 ± 0.17 CMJ282C MYB-related protein 3.87 ± 0.23 CML236C Hypothetical protein 3.32 ± 0.08 CMC183C Hypothetical protein 3.29 ± 0.12 CMJ222C Hypothetical protein 3.19 ± 0.34 CMQ313C Hypothetical protein 3.04 ± 0.20 CMM277C Hypothetical protein 3.02 ± 0.83 CMQ066C Hypothetical protein 2.95 ± 0.19 CMD108C Probable lactoylglutathione lyase 2.83 ± 0.09 CMS246C Hypothetical protein 2.79 ± 0.21 CMS149C Hypothetical protein 2.78 ± 1.85 CME036C Hypothetical protein 2.77 ± 0.50 CMQ191C Citrate synthase, mitochondrial precursor 2.74 ± 0.46 CMI233C Glutamine synthetase 2.74 ± 0.35 CMI268C Hypothetical protein 2.67 ± 0.22 CMF144C Hypothetical protein 2.67 ± 0.07 CMC149C Phosphoglycerate dehydrogenase 2.64 ± 0.45 CMI140C 60S acidic ribosomal protein P1 2.59 ± 0.59 CMI066C Hypothetical protein 2.55 ± 0.41 CMK296C Ubiquitin with short C-terminal extension 2.52 ± 0.29 CMQ064C Acetylornithine transaminase 2.51 ± 0.60 CMI118C Similar to cell death-regulatory protein GRIM19 2.51 ± 0.24 CME180C Hypothetical protein 2.42 ± 0.24 CMR492C Similar to MAP kinase
    [Show full text]